CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 124 enrolled
Drug / intervention
Quadrivalent Inactivated Influenza Vaccine +2 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03179761
NCT03179761Phase 2Completed
CompareCT.gov

High vs. Standard Dose Flu Vaccine in Adult Stem Cell Transplant Recipients

Vanderbilt-Ingram Cancer Center·interventional·Posted Jun 7, 2017·Updated Dec 4, 2024

In Brief

A Phase 2 clinical trial evaluating Quadrivalent Inactivated Influenza Vaccine, Laboratory Biomarker Analysis, and 1 other intervention for Hematopoietic Cell Transplantation. Completed, enrolled 124 participants across 4 sites.

Detailed Summary

This randomized phase II studies the side effects of high-dose trivalent influenza vaccine or standard-dose quadrivalent inactivated influenza and how well they work in treating adult patients undergoing stem cell transplant. Season influenza can cause more severe infections in patients who have had a stem cell transplant since their immune system doesn't work as well. Influenza vaccine may provide better protection against flu in adults.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHematopoietic Cell Transplantation
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
201820192020202120222023202420252026
First PostedJun 7, 2017
Enrollment StartOct 9, 2017
Primary CompletionFeb 15, 2022
Study CompletionOct 1, 2024
TodayJul 2, 2026
Enrollment to primary: 4.4 yearsPosted 9.1 years ago

Interventions

Quadrivalent Inactivated Influenza Vaccinebiological

Standard Dose Quadrivalent Influenza Vaccine given intramuscularly

Laboratory Biomarker Analysisother

Correlative studies

Trivalent Influenza Vaccinebiological

High Dose Trivalent Influenza Vaccine given intramuscularly